Lilly-Insilico AI Drug Deal Anchors China Licensing Wave

What happened

Eli Lilly has expanded its relationship with Insilico Medicine, a Hong Kong-listed company that uses generative AI to design drug candidates from target selection through molecule design. The deal was announced on 29 March 2026 24. Insilico gets $115 million upfront and could collect up to $2.75 billion in total if development, regulatory, and commercial milestones are met. It would also receive tiered royalties 15. In return, Lilly takes exclusive worldwide rights to a portfolio of preclinical programs spanning several therapeutic areas 1.

The agreement also goes beyond buying finished assets. Lilly will use Insilico's Pharma.AI platform to pursue new research programs aimed at targets Lilly selects 1. The two companies have worked together since 2023, so this is an escalation of an existing partnership, not a first date 15.

Insilico founder and CEO Alex Zhavoronkov told CNBC the company has produced at least 28 drugs with generative AI tools, and nearly half have reached clinical stages 5. Insilico listed in Hong Kong in December, and its shares had risen more than 50% so far this year 5. Zhavoronkov also said Lilly holds a competitive edge in certain aspects of AI 5. That remark suggests Lilly is buying capability and compounds, and is not simply outsourcing its thinking.

The headline number versus the cash

How you read this deal depends on which figure you focus on. General news coverage led with the $2.75 billion total 45. Deal-tracking and market-data sources pointed to the gap between that number and the money actually committed. The $115 million upfront is the only guaranteed payment. Everything else depends on programs surviving trials, and most drug candidates do not, whether AI designed them or not 1. One market analysis calls announced values in AI drug discovery "milestone-weighted," with cash at signing a small fraction of the press-release figure 2.

The wider 2026 data supports that caution. The first quarter of 2026 produced 38 AI drug discovery partnerships with $35.8 billion in potential value but only $1.7 billion upfront 2. In the second quarter, the slide was sharper: 32 deals, $10.1 billion in potential value, and just $200 million upfront. The median upfront per deal fell from $78 million to $15 million 2. M&A followed a similar pattern. Deal count rose in Q2 while total value dropped from $10.6 billion to $1.8 billion. A notable exception was Roche's agreement to pay $750 million upfront for PathAI 2.

Against that backdrop, Lilly's $115 million upfront looks relatively generous. The figure sits above the Q1 median and far above the Q2 one, and the deal ranks as the largest AI discovery agreement of the period by headline value 2. In my reading, Lilly is paying a real premium for Insilico's platform and pipeline, even if the $2.75 billion figure overstates what will change hands.

The China angle

The deal also belongs to a broader shift: Western pharma increasingly sources innovation from China. Lilly plans to invest $3 billion in China over the next decade. A record number of non-Chinese companies licensed treatments from Chinese firms in 2025 4. One analysis found that 11 large drugmakers, including Lilly, AstraZeneca, and GSK, committed more than $150 billion to licensing Chinese biotech assets over five years. Chinese-originated candidates now account for roughly 40% of licensing deals 3.

AI-native biotechs are a growing slice of that flow. Sanofi struck a second deal with Earendil Labs in January 2026, worth up to $160 million upfront and $2.56 billion in milestones, for AI-designed autoimmune biologics 3. Together with Sanofi's earlier Earendil agreement, those deals approach $4 billion in possible payments 3. Earendil also raised a $787 million funding round in March 2026 3.

Why it matters

The sources broadly agree on the facts. They differ mainly in emphasis. Coverage aimed at a general audience treats the deal as evidence that AI is speeding up drug research and that China is becoming central to global pharma 45. Financial trackers treat it as another heavily back-loaded bet 12.

Both framings hold, but the more useful takeaway is the combination. Big pharma has decided that China-based AI drug developers are a legitimate source of pipeline. It is also structuring deals so that most of the risk, and most of the payout, stays tied to clinical results. The falling upfronts in Q2 suggest buyers are getting more disciplined, not more euphoric 2.

For Insilico, the real test is not the size of the deal value. It is whether its clinical-stage AI-designed molecules can clear late-stage trials. If they do, the milestone payments will follow. If they don't, the $2.75 billion will be remembered mainly as a press-release figure.